Table 2.
Multivariate Cox regression analysis for relapse-free survival
| Multivariate HR (95% CI) | P | |
|---|---|---|
| Model 1 | ||
| Gender (female vs male) | 0.906 (0.402, 2.041) | 0.812 |
| Smoking index (> 400 vs ≤ 400) | 1.584 (0.782, 3.210) | 0.202 |
| Pathologic stage (IIIA vs IIB) | 1.310 (0.741, 2.315) | 0.352 |
| Pathologic stage (IIIB vs IIB) | 2.083 (0.600, 7.232) | 0.248 |
| TC PD-1+CD8+ (low vs high) | 2.183 (1.140, 4.184) | 0.019* |
| IM PD-1+CD4+ (low vs high) | 1.675 (0.965, 2.907) | 0.066 |
| Model 2 | ||
| Gender (female vs male) | 0.717 (0.314, 1.639) | 0.431 |
| Smoking index (> 400 vs ≤ 400) | 1.367 (0.680, 2.748) | 0.380 |
| Pathologic stage (IIIA vs IIB) | 1.079 (0.595, 1.958) | 0.801 |
| Pathologic stage (IIIB vs IIB) | 0.782 (0.203, 3.016) | 0.721 |
| IM PD-1+CD4+ effective density (high vs low) | 2.809 (1.477, 5.343) | 0.002* |
| Model 3 | ||
| Gender (female vs male) | 0.760 (0.333, 1.734) | 0.514 |
| Smoking index (> 400 vs ≤ 400) | 1.637 (0.804, 3.334) | 0.174 |
| Pathologic stage (IIIA vs IIB) | 1.192 (0.671, 2.116) | 0.550 |
| Pathologic stage (IIIB vs IIB) | 1.773 (0.514, 6.116) | 0.365 |
| IM PD-1+CD4+ effective percentage (high vs low) | 4.063 (1.979, 8.341) | 0.000* |
| Model 4 | ||
| Gender (female vs male) | 0.570 (0.227, 1.429) | 0.230 |
| Smoking index (> 400 vs ≤ 400) | 0.791 (0.351, 1.782) | 0.571 |
| Pathologic stage (IIIA vs IIB) | 1.496 (0.756, 2.962) | 0.248 |
| Pathologic stage (IIIB vs IIB) | 2.137 (0.469, 9.734) | 0.326 |
| TC PD-1+CD4+ density & effective density (lohi vs hilo) | 5.810 (1.248, 27.045) | 0.025* |
| Model 5 | ||
| Gender (female vs male) | 0.290 (0.075, 1.119) | 0.072 |
| Smoking index (> 400 vs ≤ 400) | 1.120 (0.395, 3.173) | 0.831 |
| Pathologic stage (IIIA vs IIB) | 0.792 (0.301, 2.082) | 0.637 |
| IM PD-1+CD4+ density & effective density (lohi vs hilo) | 8.709 (2.950, 25.714) | 0.000* |
HR hazard ratio, CI confidence interval. *P < 0.05